#NewDrugForDengue- Sun Pharma to develop novel botanical drug for treatment of Dengue.

411623-dengue14.09.15A global programme to develop botanical drug by Sun Pharma in collaboration with the International Centre for Genetic engineering and Biotechnology (ICGEB), New Delhi. 

  • ICGEB & Sun Pharma to combine experience, interest, knowledge & expertise for development of Cipa, a botanical drug, for treatment of dengue worldwide.
  • Sun Pharma to fund entire development programme as well pay royalty following commercialization of the drug, financial & investment details confidential.
  • ICGEB will provide the technical know-how and pre-clinical expertise.
  • Sun Pharma to develop this drug with appropriate pre-clinical & clinical studies to register it in India and other global markets
  •  International Centre for Genetic Engineering and Biotechnology (ICGEB) and  Sun Pharmaceutical Industries Ltd and includes its subsidiaries or associate companies) today signed an agreement to develop a novel botanical drug for treatment of dengue. Through this agreement, Sun Pharma commits development of Cissampelos pariera (Cipa), a botanical drug in collaboration with ICGEB.
  • Through this agreement Sun Pharma will follow up on earlier pre-clinical collaboration between ICGEB and erstwhile Ranbaxy Laboratories Ltd.
  • Sun Pharma will develop Cipa, a botanical drug following a drug registration process similar to a new chemical entity, consisting of all required in-vitro, in-vivo, pre-clinical and clinical studies meeting all regulatory standards of India and other regulatory agencies worldwide.
  • A botanical drug is a plant-derived medicinal product that is intended for use in the diagnosis,cure, mitigation, treatment or prevention of disease in humans. These medicines are based on complex botanical compounds and can offer multiple agent solution, selectively and differentially affecting various target tissues. These characteristics make botanical drugs safe and effective. As any other new drug, Sun Pharma will scientifically substantiate the safety and effectiveness, manufacture under appropriate standards and build a strong intellectual property base to support commercialization of its botanical dengue drug.